We measured significantly higher levels of Galectin-7 in plasma from squamous cell carcinoma patients than in plasma from adenocarcinoma patients, suggesting that it could serve as a biomarker for LUSC (Figure 6E, P < 0.0001). Here, LGALS7 is linked to squamous cell carcinoma.